1.Sales and profit
See section β- Polaryx Therapeutics, Inc. lost $9.0M in fiscal 2025.
Polaryx Therapeutics, Inc.
PLYX Nasdaq Pharmaceutical Preparations Financials FY2024βFY2025
- Today
- 1.6%
- Previous close
- $1.85
- Market cap
- $87.9M
- P/E
- β
- 52-week range
-
$1.82 $35.00
Last close Β· Oct 26, 2026
$1.82
β$33.18 (β94.80%) since Feb 2, 2026
KIRAβs summary AI analyst
Hi! I read Polaryx Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
1 to watch
2.Cash and shareholders
See section β- In the last 12 months, insiders bought $0.4M of shares on the open market and sold none.
Polaryx Therapeutics, Inc. in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
β$9.0M
No. It lost money last year.
For information
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
$87.9M
Oct 26 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
On β$0.20 EPS (TTM)
Charts by
Sales and profit
Is it selling more, and how much does it keep?
Revenue and margins
Revenue
FY24
Revenue β
FY25
Revenue β
Margins, % of revenue
FY24
Gross β
Operating β
Net β
FCF β
FY25
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Net income and earnings per share
Loss periods are shown in red.
KIRA summarises the numbers
-
Polaryx Therapeutics, Inc. lost $9.0M in fiscal 2025.
Net income
FY24
Net income β$30.4M
FY25
Net income β$9.0M
Net income
Q1 '25
Net income β$5.1M
Q2 '25
Net income β$1.0M
Q1 '26
Net income β$2.5M
Q2 '26
Net income β$1.4M
Diluted EPS
FY24
Diluted EPS β$0.89
FY25
Diluted EPS β$0.20
Diluted EPS
Q1 '25
Diluted EPS β$0.11
Q2 '25
Diluted EPS β$0.02
Q1 '26
Diluted EPS β$0.05
Q2 '26
Diluted EPS β$0.03
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
Cash from operations minus capital spending.
Free cash flow
FY24
Free cash flow β
FY25
Free cash flow β
Cash from operations vs capital spending
FY24
Cash from operations β$2.6M
Capital spending β
FY25
Cash from operations β$3.9M
Capital spending β
Cash from operations
Capital spending
Cash from operations vs capital spending
Q1 '25
Cash from operations β$0.7M
Capital spending β
Q2 '25
Cash from operations β$0.9M
Capital spending β
Q1 '26
Cash from operations β$2.1M
Capital spending β
Q2 '26
Cash from operations β$1.4M
Capital spending β
Cash from operations
Capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Dividends, buybacks and share count
Dividends and buybacks
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY24
Diluted shares 0.03B
FY25
Diluted shares 0.05B
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
-
In the last 12 months, insiders bought $0.4M of shares on the open market and sold none.
Bought, 12 months
$0.4M
2 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 27, 2026 | Mstone Partners Healthcare LtdDirector, 10% owner | Bought | 88,453 | $4.07 | $0.4M | Form 4 |
| Feb 18, 2026 | G. Michael LandisChief Financial Officer, Director | Bought | 2,867 | $2.79 | $0.0M | Form 4 |
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably Polaryx Therapeutics, Inc. can carry it.
Cash vs debt (incl. leases)
FY24
Cash $4.6M
Debt β
FY25
Cash $5.1M
Debt β
Cash
Debt
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | $4.6M | $5.1M |
| Current ratio | 17.3x | 8.5x |
| Quick ratio | 17.3x | 8.5x |
| Total assets | $5.0M | $5.2M |
| Total liabilities | $0.3M | $0.6M |
| Shareholders' equity | $4.7M | $4.6M |
| Net debt (β = net cash) | β | β |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Return on capital, equity and assets (annual)
FY24
Return on capital β
Return on equity β644.2%
Return on assets β607.0%
FY25
Return on capital β
Return on equity β193.7%
Return on assets β176.7%
Return on capital
Return on equity
Return on assets
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | β | β |
| Cash from operations is positive | β | β |
| Return on assets rose | β | β |
| Cash from operations exceeds net income | β | β |
| Debt fell relative to assets | β | β |
| Current ratio rose | β | β |
| Share count didn't rise | β | β |
| Gross margin rose | β | β |
| Revenue rose relative to assets | β | β |
| F-score | β / 3 | β / 6 |
| Accruals ratio | β555.5% | β99.1% |
| Altman Z'' | β41.64 | β59.28 |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
All figures
Every number, year by year.
2 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Research and development | $2.8M | $6.3M |
| Operating income | β$4.4M | β$7.8M |
| Pretax income | β$30.4M | β$9.0M |
| Net income | β$30.4M | β$9.0M |
| Diluted EPS | β$0.89 | β$0.20 |
| Diluted shares | 0.03B | 0.05B |
| Cash flow | ||
| Cash from operations | β$2.6M | β$3.9M |
| Stock-based compensation | $2.4M | $4.7M |
| Balance sheet | ||
| Cash and short-term investments | $4.6M | $5.1M |
| Current assets | $5.0M | $5.2M |
| Current liabilities | $0.3M | $0.6M |
| Total assets | $5.0M | $5.2M |
| Total liabilities | $0.3M | $0.6M |
| Shareholders' equity | $4.7M | $4.6M |
| Returns | ||
| Return on capital employed | β92.4% | β171.3% |
| Return on equity | β644.2% | β193.7% |
| Return on assets | β607.0% | β176.7% |
| Return on tangible equity | β644.2% | β196.8% |
| Growth | ||
| Share count change | β | 32.8% |
| Financial health | ||
| Current ratio | 17.3x | 8.5x |
| Quick ratio | 17.3x | 8.5x |
| Quality scores | ||
| Altman Z'' | β41.6 | β59.3 |
| Accruals ratio | β555.5% | β99.1% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
Source: SEC EDGAR XBRL filings (CIK 0002075320). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.